BioStock: Elicera’s CEO: ” iTANK has great potential in treating solid tumours”

Elicera’s Q3 report was filled with updates from the ongoing cell therapy projects, where they see potential value-driving milestones in the near future. BioStock talked to Elicera’s CEO and co-founder Jamal El-Mosleh, who shares his view about the short-term goals, but also about the overarching long-term goal – to out-license the company’s platform technology iTANK to CAR T-developing pharmaceutical companies worldwide.

Read the full interview with Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2023/11/eliceras-ceo-itank-has-great-potential-in-treating-solid-tumours/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/